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A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo
expansion of human primary multiple myeloma cells
Leukemia (2011) 25, 707–711; doi:10.1038/leu.2010.300;
published online 14 January 2011
Multiple myeloma (MM) cells home to the bone marrow (BM)
and adhere to extracellular matrix (ECM) proteins and to bone
marrow stromal cells (BMSCs). The close cross talk between MM
cells and cells of the non-tumor compartment within the BM has
a key role in supporting tumor growth, survival and develop-
ment of drug resistance. This biological scenario has led to a
growing interest in novel drugs, targeting MM cells and/or
interfering with their human BM milieu (HuBMM).
1,2 Based on
this, appropriate in vivo models that recapitulate the complex
interactions occurring between MM and its HuBMM are required
for preclinical evaluation of new anti-MM agents. To date, the
in vivo study of MM pathobiology and the validation of
therapeutic anti-MM agents has been carried out using a variety
of models of murine MM or human MM xenografts in
immunocompromised mice.
3 These models, however, do not
replicate the HuBMM. The development of the SCID (severe
combined immunodeﬁciency)-hu model has been an important
advance, as it was the ﬁrst model to recapitulate a HuBMM in
mice.
4–6 However, although the SCID-hu system remains a highly
relevant model for preclinical investigation, it does have important
limitations: (i) restricted availability of human fetal bone chips;
(ii) the allogeneic nature of the fetal BM milieu versus MM cells;
and (iii) the signiﬁcant heterogeneity of implanted human bone
chips, collected from different individuals at different gestational
age, that may produce experimental variability.
With the aim to overcome the limitations of the SCID-hu
system, here, we report the development of a novel in vivo
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Figure 1 (A) SEM analysis of a PCLS ( 65 (1),  500 (2),  650 (3) and  1200 (4) magniﬁcation) shows interconnected large and small pores
(white bars¼1mm (1), 200mm (2), 100mm (3) and 50mm (4)). (B) Comparative SEM analysis ( 150 magniﬁcation) between a synthetic PCLS
(upper panel) and a surgical sample of human femur adult bone (lower panel) shows similar microarchitecture (white bars¼500mm). Surface
morphology was studied by a Leica Cambridge (Stereoscan S440) SEM (Cambridge, UK) at an accelerating potential of 20kV. (C) H&E staining of
adherent OP9 mouse stromal cells at 3 weeks after scaffold implant in mice. (D–F) SEM analysis ( 3500 magniﬁcation) (d), H&E staining (e) and
confocal laser scanning microscopy (f) show adherence within a PCLS of human BMSCs, obtained from two different patients (pt #3, (a); pt #7,
(b) See Table 1), 1 week after implant in mice. (G) Flow chart diagram. Schematic representation of experimental methodology.
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www.nature.com/leuhuman MM model based upon the implantation into a SCID
mouse of a three-dimensional (3D) bone-like poly-e-caprolac-
tone polymeric scaffold (PCLS). In this model, we demonstrated
efﬁcient coating of the 3D scaffold internal surface with mouse
or human BMSCs and successful engraftment of human primary
explanted MM cells within their autologous HuBMM in vivo.
Using a previously described methodology,
7 we synthesized
PCLSs cylinders (7mm in length and 3mm in diameter)
that, at scanning electron microscope (SEM), demonstrated
interconnected large (100–300mm) and small pores (1–10mm)
(Figure 1A), resembling the microarchitecture of a normal
human femur adult bone (Figure 1B). PCLSs were stored
at 41C in ethanol 70% and then were maintained overnight in
50ml of sterile water before use. In these PCLSs, we ﬁrst seeded
OP9 cells, a mouse BMSC line, to set up the experimental
loading conditions. As OP9 cells efﬁciently adhered to 3D
surfaces (Figure 1C), we next evaluated the suitability of these
PCLSs to host human BMSCs derived from MM patients. OP9
mouse BMSCs were cultured in a-MEM (GIBCO, Invitrogen, San
Giuliano Milanese (MI), Italy) containing 10% heat-inactivated
fetal bovine serum. Human BMSCs were obtained with long-
term culture (28 days) of bone marrow mononuclear
cells (BMMCs) from Ficoll gradient separation
of BM aspirates.
8 Dynamic seeding of BMSCs into PCLSs was
performed in vitro using a suspension of 10
6 cells in 500mlo f
growth medium. A 22-gauge needle on a 2.5ml syringe was
threaded into two ending face of the cylindrical scaffold.
A medium ﬂow rate of 500ml/min and three drawing cycles
were carried out on both scaffold ends. Before implantation,
PCLSs were incubated in complete medium at 371Ci n5 %C O 2
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Figure 2 (a) Histological and immunohistochemical (anti-CD138/MI15 (Dako, Dako Itala S.p.A., Milano, Italy), anti-k (Dako) and anti-l (Dako))
analysis of retrieved PCLSs. Line 1 shows unselected BMMCs; line 2 shows selected CD138þ on heterologous BMSCs; line 3 shows selected
CD138þ from PB of a PCL patient on heterologous BMSCs; and line 4 shows IL-6-dependent INA-6 MM cells on heterologous BMSCs. Anti-
human k-light chains and anti-human l-light chains were used (Dako). Dilutions were 1:15000 for k-light chains and 1:10000 for l-light chains.
(b) Ki-67 staining of MM-bearing PCLSs retrieved 3–4 months after cell injection. (c, d) Kinetics of appearance of paraproteins in sera from
representative SCID-synth-hu mice engrafted with samples from MM patients. A code for each patient sample is provided according to Table 1. Left
panel includes seven samples from patients with whole paraprotein (ELISA, GenWay Biotech Inc., San Diego, CA, USA); right panel includes two
patients with light chain MM (ELISA, Bethyl Laboratories Inc., Montgomery, TX, USA).
Letters to the Editor
708
Leukemiafor 24h to allow cell adhesion on 3D surfaces. Then, the PCLS
was surgically implanted subcutaneously into a SCID mouse
ﬂank. Chloralium hydrate anesthesia (400mg/kg) was used
during all surgical procedures. Figure 1G shows the ﬂow chart
diagram of experimental procedures. As shown in Figures 1D–F,
cultured human BMSCs adhered and spreaded among 3D
interconnected surfaces, starting 1 week after cell injection, as
demonstrated by SEM, hematoxylin and eosin (H&E) staining
and confocal laser scanning microscopy. Based on these
achievements, we next evaluated the suitability of these
BMSCs-coated PCLSs for engraftment of primary MM cells and
interleukin-6 (IL-6)/BM-dependent INA-6MM cell line.
CD138
þ immunoselected primary MM cells from BM aspirates
of patients with newly diagnosed (n¼5) or plasma cell leukemia
(PCL, n¼1), and from peripheral blood of PCL patients (n¼2),
as well as INA-6 cells were injected in vivo in previously
implanted PCLSs that, 3 weeks before, were coated ex vivo
with BMSCs. Importantly, although both primary MM cells and
IL-6/BM-dependent INA-6 MM cells successfully engrafted in
human BMSCs-coated PCLSs, they did not engraft into scaffolds
previously coated with murine BM stromal cell line OP9 or
empty PCLSs. This ﬁnding is in agreement with previous
observations in the SCID-hu model, where primary MM or
INA-6 cells did not inﬁltrate mouse bone or other murine
organs.
5,6 These observations suggest that species-speciﬁc
interactions allow MM in vivo growth in our system.
With the aim to overcome one of the important limitations
associated with the SCID-hu model, we further attempted to
engraft primary MM cells within their autologous HuBMM.
To achieve this aim, we injected unselected BMMCs, obtained
by Ficoll gradient separation of BM aspirate of MM patients,
into PCLSs. This unselected BMMC suspension, containing both
primary CD138
þ MM cells and their autologous BMSCs,
was freshly seeded ex vivo in uncoated PCLSs before in vivo
implantation of the scaffold in SCID mouse ﬂank (Figure 1g,
ﬂow chart diagram). Notably, we achieved a successful
engraftment of all patient samples (Figure 2, Table 1). Clinical
features of donor MM patients and the actual rate of MM
engraftment in SCID-synth-hu mice are reported in Table 1.
As shown in Figure 2a, retrieved PCLSs from SCID-synth-hu
mice injected with CD138
þ immunoselected primary MM cells
or unselected BMMCs containing primary MM cells, or INA-6
MM cells demonstrated engraftment and ﬁlling of 3D spaces by
tumor cells, as conﬁrmed by both H&E and CD138 or k/l
staining. As we observed slow progressive degradation of PCLSs
in mice, long-term survival of MM cells and active proliferation
were demonstrated by Ki-67 staining 3–4 months after
cell injection (Figure 2b). Following 3–4 weeks, MM cell growth
was monitored in vivo by enzyme-linked immunosorbent
assay detection of human heavy or light chains in mouse sera
(Figures 2c and d). Moreover, to assess the suitability of this
model for preclinical evaluation of anti-MM agents, we next
treated MM-bearing SCID-synth-hu mice intraperitoneally with
bortezomib (on days 1, 4, 8 and 11) and dexamethasone
(on days 1–4). Such regimen dramatically inhibited MM cell
growth in vivo, as demonstrated by the fall of paraprotein levels
in mouse sera (Figure 3a) and by the detection of MM cell
apoptosis in retrieved PCLSs (Figure 3b), as compared with
untreated control mice. These results clearly demonstrated that
this model is actually suitable for large-scale in vivo preclinical
screening of investigational anti-MM drugs. An additional
important observation was the detection of vasculogenetic
events in retrieved PCLSs. In fact, H&E and immunohistochem-
ical staining demonstrated vasculogeneic activity together with
the presence of a neosynthesized ECM (Figure 3c). Both in
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LeukemiaBMSCs-coated PCLSs injected with MM cells and in scaffolds
directly implanted with BMMCs, we observed vessels of variable
size and human-derived endothelial cells as demonstrated by
reactivity of a speciﬁc anti-human CD31mAb. The vasculo-
genetic activity mostly occurred within areas of MM inﬁltration
(Figure 3 c3). These ﬁndings suggest a role of human
vasculogenesis in our system.
All together, our ﬁndings demonstrate that the SCID-synth-hu
is a novel model for in vivo engraftment of human primary MM
cells within their autologous adult HuBMM. This model offers
several potential advantages as compared with the SCID-hu
system that includes the unlimited availability of PCLSs, the
ability to dissect biological events within the HuBMM and,
most importantly, the engraftment of primary MM cells in a
non-fetal adult autologous HuBMM. Moreover, the present
model represents the ﬁrst system for in vivo expansion of human
MM cells on a synthetic platform. We conclude that the SCID-
synth-hu is a unique tool for large-scale in vivo preclinical
evaluation of novel agents targeting MM in an autologous
HuBMM and a novel resource for translational research in the
experimental treatment of this still incurable disease.
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Figure 3 (a) SCID-synth-hu mice were treated intraperitoneally with bortezomib (1mg/kg)þdexamethasone (1mg/kg). The black arrows indicate
the time of treatment. (b) H&E staining of a MM-bearing PCLS, engrafted with primary MM cells, following BortþDex treatment showed diffuse
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Differential expression of the BCR gene in sequential stages of murine hematopoietic
hierarchy
Leukemia (2011) 25, 711–713; doi:10.1038/leu.2010.303;
published online 14 January 2011
The recent manuscript by Marega et al.
1 entitled ‘BCR and
BCR-ABL regulation during myeloid differentiation in healthy
donors and chronic phase/blast crisis chronic myeloid leukemia
patients’, which reported the BCR expression during the
different stages of maturation of human myeloid cells provides
important insight into the nature of chronic myeloid leukemia,
particularly the similarity of BCR and BCR-ABL differential
expression patterns during myeloid maturation in healthy
subjects and patients with chronic-phase chronic myeloid
leukemia, respectively. We studied the expression of BCR
transcripts in the murine hematopoiesis. Similar to Marega et al.,
we found that BCR is differentially expressed during murine
hematopoietic maturation. Further, our ﬁndings begin to address
one of the conundrums ensuing from the work by Dr Eaves and
her team in which it was reported that BCR-ABL transduction of
mouse bone marrow resulted in expansion of granulocytes,
lymphocytes and erythrocyte.
2
In fact, we performed our quantitative BCR transcript expression
analysis in detailed stages of the murine hematopoietic hierarchy
by assessing RNA obtained from single-cell progenitors with
known fate, a strategy that has been previously published.
3–6
The different stages of murine hematopoiesis that were analyzed
included the long-term repopulating hematopoietic stem cells
(LTR-HSCs) that are characterized by the phenotype (Rho
lo/Kit
þ/
Sca1
þ/Lin
 /CD49b
lo) and able to repopulate the entire hemato-
poietic system for more than a year,
6 the intermediate-term
repopulating hematopoietic stem cells (ITR-HSCs) that have
the phenotype (Rho
lo/Kit
þ/Sca1
þ/Lin
 /CD49b
hi) and are able
to repopulate the entire hematopoietic system for 3–12 months,
6
the multipotent Bþ (which have clonal potential erythroid (E),
megakaryocytic (Meg), macrophagic (Mac), neutrophilic (Neut),
mastocytic (Mast) and B lymphocyte (B)), pentapotent (with the
potential E, Meg, Mac, Neut and mastocytic), the tetrapotent (with
the potential E, Meg, Mac and Neut), the bipotent (pE/pMeg and
pNeut/pMac), the unipotent (burst-forming unit-erythroid, colony-
forming unit-erythroid, pMeg, pMac and pNeut) progenitors and,
ﬁnally, the terminally differentiated cells (E, Meg, Mac, Neut,
mastocytic, B and T); the lineage potentials of the different cells
sampled are summarized in Figure 1a. Complementary DNA was
obtained from sorted cells (LTR-HSCs, ITR-HSCs, mature B and
mature T) or pooled from single cells, differentiation potential
of which was determined by the outcome of cultured sibling cells
(the multipotent Bþ, the pentapotent, the tetrapotent, the
bipotent, the unipotent and the terminally differentiated cells). In
addition, we also analyzed BCR gene transcript levels in HSCs that
were harvested from normal marrow in G0 phase and after
stimulation, with Kit ligand, Flt3 ligand and IL-11, in culture to
undergo mitosis. Furthermore, we compared BCR expression in
LTR-HSCs and ITR-HSCs at entry into cell cycle (G1 phase) and
again at a point when half of the cells had undergone mitosis (M
phase); the distinction between these two stages was done on the
basis of morphological criteria.
Indeed, high BCR transcript levels were seen in LTR-HSCs and
interestingly in the pE/Meg progenitors (BCR/glyceraldehyde-3-
phosphate dehydrogenase of 0.008 and 0.0093, respectively) (Figure
1a and b), intermediate levels were found in ITR-HSCs and
pentapotent and pNeut/Mac cells (BCR/glyceraldehyde-3-phosphate
dehydrogenase ratios of 0.0022, 0.001 and 0.002, respectively),
whereas low levels were detected in pMeg, pMac, pNeut, Meg and
Neut (0.000231, 0.000073, 0.000239, 0.000158 and 0.000169)
(Figure 1a and b). Finally, BCR Expression was not detected in the
multipotent Bþ, tetrapotent, burst-forming unit-erythroid, colony-
forming unit-erythroid and the terminally-differentiated cells (E,
Mac, mastocytic, B and T) (Figure 1a and b). We also analyzed BCR
gene transcript levels in HSCs that were harvested from normal
marrow in G0 phase and after stimulation, in culture to undergo
mitosis. Interestingly, when BCR transcript levels were compared in
LTR-HSCs and ITR-HSCs harvested from normal marrow in G0
phase and after stimulation to undergo mitosis, cycling LTR-HSCs
and ITR-HSCs showed 7.6- and 4.3-fold increase, respectively, in
BCR transcripts (Figure 1c).
Although we used different methodology for deﬁning the different
stages of hematopoietic maturation, our results indicate that the
expression of BCR during the different stages of murine hematopoi-
esis are consistent with the results reported by Marega et al.
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